Pfiz­er, Astel­las tout pos­i­tive PhI­II da­ta to po­ten­tial­ly ex­pand Xtan­di la­bel

Pfiz­er and Astel­las are gun­ning to add a fourth in­di­ca­tion to their can­cer drug Xtan­di with Phase III tri­al re­sults re­leased to­day.

The study, look­ing at Xtan­di plus le­upro­lide and Xtan­di as a monother­a­py in men with non-metasta­t­ic hor­mone-sen­si­tive prostate can­cer, met its pri­ma­ry end­point with a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment” in metas­ta­sis-free sur­vival in the pa­tients treat­ed with Xtan­di plus le­upro­lide, ac­cord­ing to the com­pa­nies, though no de­tailed da­ta was giv­en.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER